Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatmentTheresia M. Westers, Arjan A. van de Loosdrecht, Gert J. Ossenkoppele et al.|Blood|2009Cited by 92
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndromeMartine E.D. Chamuleau, Arjan A. van de Loosdrecht, Theresia M. Westers et al.|Haematologica|2009Cited by 72